当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association.

Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association.

Abstract：

BACKGROUND:Population data supporting an association between the autoimmune cholestatic liver diseases, primary biliary cirrhosis and primary sclerosing cholangitis and coeliac disease, is limited and at times contradictory. AIM:To explore the relationship between coeliac disease and both primary biliary cirrhosis and primary sclerosing cholangitis within the General Practice Research Database, a UK-based longitudinal primary care database. METHODS:We identified 4732 people with diagnosed coeliac disease and 23 620 age- and sex-matched controls within the General Practice Research Database. We calculated the prevalence of primary biliary cirrhosis and primary sclerosing cholangitis for both the coeliac disease and control group. RESULTS:There was a higher prevalence of primary biliary cirrhosis in adults with coeliac disease, compared with controls [0.17% vs. 0.05%, odds ratio 3.63 (95% confidence interval: 1.46-9.04)]. Primary sclerosing cholangitis was also more common in the coeliac disease group [0.04% vs. 0%, fishers exact test (P = 0.03)]. CONCLUSIONS:There was a threefold or greater increase in risk of both primary biliary cirrhosis and primary sclerosing cholangitis in people with coeliac disease compared with the general population. The association with primary biliary cirrhosis was weaker than in some reports and it is difficult on the basis of this study to justify screening patients with coeliac disease for either primary biliary cirrhosis or primary sclerosing cholangitis.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Lawson A,West J,Aithal GP,Logan RF

doi

10.1111/j.1365-2036.2005.02328.x

subject

Has Abstract

pub_date

2005-02-15 00:00:00

pages

401-5

issue

4

eissn

0269-2813

issn

1365-2036

pii

APT2328

journal_volume

21

pub_type

杂志文章,评审

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • The use of adalimumab in the management of refractory Crohn's disease.

    abstract：BACKGROUND:Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor-alpha. Recent clinical trials have demonstrated its efficacy in Crohn's disease; however, experience in clinical practice remains limited. AIM:To investigate the efficacy and safety of adalimumab in the clinical setting. METHODS...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.2007.03583.x

    authors： Ho GT,Smith L,Aitken S,Lee HM,Ting T,Fennell J,Lees CW,Palmer KR,Penman ID,Shand AG,Arnott ID,Satsangi J

    更新日期：2008-02-15 00:00:00

  • Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions.

    abstract：:Despite implementation of screening and surveillance strategies, a significantly large number of patients with Barrett's oesophagus remain undiagnosed. In those who are identified, the management options include acid reduction therapies with proton pump inhibitors or anti-reflux surgery. Endoscopic ablative therapies ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.0953-0673.2004.01839.x

    authors： Jankowski J,Sharma P

    更新日期：2004-02-01 00:00:00

  • Mycophenolate mofetil in refractory inflammatory bowel disease.

    abstract：BACKGROUND:Mycophenolate mofetil has been claimed to be effective and well tolerated in refractory inflammatory bowel disease although there is little information regarding its use in clinical practice. AIM:To review our experience in achieving and maintaining remission in refractory inflammatory bowel disease and to ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2003.01581.x

    authors： Ford AC,Towler RJ,Moayyedi P,Chalmers DM,Axon AT

    更新日期：2003-06-01 00:00:00

  • Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.

    abstract：BACKGROUND:Serum vitamin D levels are associated with bone complications in patients with primary biliary cirrhosis (PBC). Increasing evidence suggests a nonskeletal role of vitamin D in various autoimmune and liver diseases. AIM:To investigate the clinical relevance of vitamin D levels in PBC, especially their associ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13244

    authors： Guo GY,Shi YQ,Wang L,Ren X,Han ZY,Guo CC,Cui LN,Wang JB,Zhu J,Wang N,Zhang J,Cai Y,Han Y,Zhou XM,Fan DM

    更新日期：2015-07-01 00:00:00

  • Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.

    abstract：BACKGROUND:Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti-viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment response is yet unclear. AIM:To study the degree of on-treatment viral anti...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.16172

    authors： Brakenhoff SM,de Man RA,Boonstra A,van Campenhout MJH,de Knegt RJ,van Bömmel F,van der Eijk AA,Berg T,Hansen BE,Janssen HLA,Sonneveld MJ

    更新日期：2021-01-01 00:00:00

  • Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.

    abstract：BACKGROUND:Little data are available regarding the effectiveness and associated microbiome changes of faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in children, especially in those with inflammatory bowel disease (IBD) with presumed underlying dysbiosis. AIM:To investigate C. diffic...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13326

    authors： Hourigan SK,Chen LA,Grigoryan Z,Laroche G,Weidner M,Sears CL,Oliva-Hemker M

    更新日期：2015-09-01 00:00:00

  • Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease.

    abstract：BACKGROUND:The effect of anti-viral treatment on downstream costs for hepatitis C virus (HCV)-infected patients is unknown. AIM:To evaluate follow-up costs in patients with chronic HCV, stratified by liver disease severity. METHODS:Using a US private insurance database, mean all-cause per-patient-per-month (PPPM) US ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12454

    authors： Gordon SC,Hamzeh FM,Pockros PJ,Hoop RS,Buikema AR,Korner EJ,Terrault NA

    更新日期：2013-10-01 00:00:00

  • Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.

    abstract：BACKGROUND:Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis C virus (HCV). Suboptimal linkage to specialists and access to DAAs are the leading barriers to treatment; however, data are limited. AIM:To determine predictors of follow-up, receipt of DAAs, and reasons for the lack thereof. METHO...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14328

    authors： Lin M,Kramer J,White D,Cao Y,Tavakoli-Tabasi S,Madu S,Smith D,Asch SM,El-Serag HB,Kanwal F

    更新日期：2017-11-01 00:00:00

  • Review article: albumin for circulatory support in patients with cirrhosis.

    abstract：:Renal function abnormalities and ascites in cirrhosis are the final consequence of a circulatory dysfunction characterized by marked splanchnic arterial vasodilation. This causes a reduction in effective arterial blood volume and the homoeostatic activation of vasoconstrictor and sodium-retaining systems. Albumin is v...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.16.s5.4.x

    authors： Ginès P,Guevara M,De Las Heras D,Arroyo V

    更新日期：2002-12-01 00:00:00

  • Review article: colon-saving medical therapy vs. colectomy in ulcerative colitis - the case for colectomy.

    abstract：:In the era of expanding medical therapy for ulcerative colitis, surgery is still a very valid option in those patients, where medicine is not able to control symptoms, both in the acute and chronic stages, and also for those at risk of developing a cancer. The ileal pouch-anal anastomosis (IPAA) will, for the vast maj...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.03065.x

    authors： Oresland T

    更新日期：2006-10-01 00:00:00

  • A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors.

    abstract：BACKGROUND:Proton pump inhibitor (PPI) use is associated with an increased risk of Clostridium difficile infection (CDI), though the mechanism is unclear. PPI induced alterations to the gut microbiome may facilitate the emergence of CDI, though the effects of PPIs on gut microbiota are not well characterised. [Correcti...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13568

    authors： Clooney AG,Bernstein CN,Leslie WD,Vagianos K,Sargent M,Laserna-Mendieta EJ,Claesson MJ,Targownik LE

    更新日期：2016-05-01 00:00:00

  • Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.

    abstract：BACKGROUND:Patients with chronic hepatitis C virus and advanced fibrosis or cirrhosis are at risk for disease progression and hepatic decompensation. AIM:To determine the effects on hepatic histology of treatment with peginterferon alfa-2a (90 or 180 mug/week) or interferon alfa-2a (3 million units three times weekly)...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2008.03620.x

    authors： Everson GT,Balart L,Lee SS,Reindollar RW,Shiffman ML,Minuk GY,Pockros PJ,Govindarajan S,Lentz E,Heathcote EJ

    更新日期：2008-04-01 00:00:00

  • Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.

    abstract：BACKGROUND:Adverse events leading to discontinuation or dose reduction of thiopurine therapy occur in 9-28% of patients with inflammatory bowel disease. AIMS:To evaluate the influence of thiopurine methyltransferase status and thiopurine metabolites in a large patient population for the risk of developing adverse even...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2006.02977.x

    authors： Hindorf U,Lindqvist M,Hildebrand H,Fagerberg U,Almer S

    更新日期：2006-07-15 00:00:00

  • Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children.

    abstract：AIM:To compare the results of culture and epsilometer test with fluorescence in situ hybridization for the detection of Helicobacter pylori and the presence of clarithromycin-susceptible and clarithromycin-resistant strains in antral biopsies from children. METHODS:Antral biopsies from 149 unselected children were inv...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2002.01382.x

    authors： Feydt-Schmidt A,Rüssmann H,Lehn N,Fischer A,Antoni I,Störk D,Koletzko S

    更新日期：2002-12-01 00:00:00

  • Effects of ranitidine on maternal gastric juice and neonates when administered prior to caesarean section.

    abstract：:Ranitidine hydrochloride, a histamine H2-receptor antagonist, was intravenously administered to 61 pregnant women at a dose of 50 mg as premedication for caesarean section; its effects on gastric secretion were studied in the mother and the newborn. The volume of the maternal gastric juice collected immediately after ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.1991.tb00033.x

    authors： Ikenoue T,Iito J,Matsuda Y,Hokanishi H

    更新日期：1991-06-01 00:00:00

  • Review article: The diagnosis of coeliac disease.

    abstract：:Coeliac disease is a chronic inflammatory condition associated with small intestinal injury that results in the malabsorption of different nutrients. The damaging factor is gluten present in wheat, barley and rye. The diagnosis relies on the clinical picture of the patient, serological markers for coeliac disease, cha...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2003.01442.x

    authors： Abdulkarim AS,Murray JA

    更新日期：2003-04-01 00:00:00

  • Systematic review: worldwide variation in the frequency of coeliac disease and changes over time.

    abstract：BACKGROUND:Coeliac disease (CD), originally thought to be largely confined to Northern Europe and Australasia and uncommon in North America and the Middle East, is now recognised to be equally common in all these countries. It is still thought to be rare in the Orient and Sub-Saharan Africa. AIM:To assess geographical...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12373

    authors： Kang JY,Kang AH,Green A,Gwee KA,Ho KY

    更新日期：2013-08-01 00:00:00

  • Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.

    abstract：BACKGROUND:The therapeutic efficacy of 5-aminosalicylic acid in inflammatory bowel disease may be related to its antioxidant properties. AIM:To compare in vitro the antioxidant effects of conventional drugs (5-aminosalicylic acid, corticosteroids, metronidazole), with new aminosalicylates (4-aminosalicylic acid, balsa...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1999.00484.x

    authors： Simmonds NJ,Millar AD,Blake DR,Rampton DS

    更新日期：1999-03-01 00:00:00

  • Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.

    abstract：BACKGROUND:Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain. AIM:To conduct a French national survey on TNF antagonists use in inflammatory bowel disease (IBD). METHODS:A postal questionnaire was sent to all French gastroenterologists among whom 4...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2009.04097.x

    authors： Oussalah A,Roblin X,Laharie D,Filippi J,Flamant M,Faure P,Phelip JM,Bigard MA,Peyrin-Biroulet L

    更新日期：2009-10-15 00:00:00

  • Review article: the diagnosis and treatment of haematinic deficiency in gastrointestinal disease.

    abstract：:Deficiency of any of the vitamins and minerals essential for normal erythropoiesis (haematinics), including iron, copper, cobalt, vitamins A, B12, B6, C, E, folic acid, riboflavin and nicotinic acid, may be associated with defective erythropoiesis and anaemia. Iron, vitamin B12 and folate are the haematinics for which...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.1998.00368.x

    authors： Pawson R,Mehta A

    更新日期：1998-08-01 00:00:00

  • Oral or intravenous erythromycin has no effect on human distal colonic motility.

    abstract：:Erythromycin is a prokinetic agent for the lower oesophageal sphincter, the stomach, the gallbladder and the small bowel, acting directly on motilin receptors. Its effect on pressure activity of the human colon has not been investigated. Eight healthy volunteers were studied on 2 occasions and given intravenous or ora...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1992.tb00573.x

    authors： Jameson JS,Rogers J,Misiewicz JJ,Raimundo AH,Henry MM

    更新日期：1992-10-01 00:00:00

  • Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection.

    abstract：BACKGROUND:Clearance of hepatitis B surface antigen (HBsAg) indicates clinical control of hepatitis B virus (HBV) infection. However, little is known about the impact of viral genomic variations on HBsAg loss. METHODS:We explored the association between viral genomic factors and HBsAg loss in 2121HBeAg-negative patien...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13170

    authors： Tseng TC,Liu CJ,Chen CL,Yang WT,Yang HC,Su TH,Wang CC,Kuo SF,Liu CH,Chen PJ,Chen DS,Kao JH

    更新日期：2015-05-01 00:00:00

  • Review article: the burden of illness of non-cardiac chest pain.

    abstract：BACKGROUND:Non-cardiac chest pain is a common condition affecting approximately one-quarter of the population during their lifetime, but the long-term economic costs of non-cardiac chest pain are poorly defined. METHODS:A MEDLINE and Current Contents search was performed from 1991 to 2002 using specific keywords. All ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2002.01296.x

    authors： Eslick GD,Coulshed DS,Talley NJ

    更新日期：2002-07-01 00:00:00

  • Review article: intra-oesophageal impedance monitoring for the assessment of bolus transit and gastro-oesophageal reflux.

    abstract：BACKGROUND:Intra-oesophageal impedance monitoring can be used to assess the clearance of a swallowed bolus (oesophageal transit) and to detect gastro-oesophageal reflux independent of its acidity. AIM:To discuss the clinical application of the impedance technique for the assessment of bolus transit and gastro-oesophag...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2008.03863.x

    authors： Conchillo JM,Smout AJ

    更新日期：2009-01-01 00:00:00

  • Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.

    abstract：BACKGROUND:Optimal management approach is not well defined for subjects who fail initial first- and second-line Helicobacter pylori eradication attempts and are dealt on a case-by-case basis by the specialists. AIM:To evaluate the efficacy and safety of standard and 'rescue' eradication therapies at primary and second...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2004.02210.x

    authors： Qasim A,Sebastian S,Thornton O,Dobson M,McLoughlin R,Buckley M,O'Connor H,O'Morain C

    更新日期：2005-01-01 00:00:00

  • Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.

    abstract：BACKGROUND:Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). AIMS:To evaluate the efficacy and safety of tacrolimus in patients with IBD...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.15687

    authors： Rodríguez-Lago I,Castro-Poceiro J,Fernández-Clotet A,Mesonero F,López-Sanromán A,López-García A,Márquez L,Clos-Parals A,Cañete F,Vicuña M,Nantes Ó,Merino O,Matallana V,Gordillo J,Elorza A,Vicente R,Casanova MJ,Ferreiro-

    更新日期：2020-05-01 00:00:00

  • There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia.

    abstract：BACKGROUND:The relationship between Helicobacter pylori infection and non-ulcer dyspepsia is not established. AIM:To determine whether eradication of H. pylori might be of benefit in non-ulcer dyspepsia patients. METHODS:We randomly assigned 129 H. pylori infected patients with severe epigastric pain, without gastro-...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.2001.01014.x

    authors： Bruley Des Varannes S,Fléjou JF,Colin R,Zaïm M,Meunier A,Bidaut-Mazel C

    更新日期：2001-08-01 00:00:00

  • Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?

    abstract：BACKGROUND:The presence of the gastric pathogen, Helicobacter pylori influences acid suppression by proton pump inhibitors and treatment outcome in patients with gastro-oesophageal reflux disease. AIM:To determine the influence of H. pylori infection on effectiveness of rabeprazole in primary and secondary care patien...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2004.02096.x

    authors： Wit NJ,Boer WA,Geldof H,Hazelhoff B,Bergmans P,Tytgat GN,Smout AJ

    更新日期：2004-08-15 00:00:00

  • Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.

    abstract：BACKGROUND:One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. AIM:To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluo...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.2000.00846.x

    authors： Cammarota G,Cianci R,Cannizzaro O,Cuoco L,Pirozzi G,Gasbarrini A,Armuzzi A,Zocco MA,Santarelli L,Arancio F,Gasbarrini G

    更新日期：2000-10-01 00:00:00

  • Review article: is stringent control of gastric pH useful and practical in GERD?

    abstract：:As the relative efficacy of therapeutic agents in the treatment of gastro-oesophageal reflux disease is related to how consistently and completely gastric acid secretion is suppressed, intragastric pH monitoring is a useful tool in stratifying therapies. If there is no acid in the stomach, there can be none to reflux ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2004.02135.x

    authors： Kahrilas PJ

    更新日期：2004-10-01 00:00:00